What Релвар Эллипта Treats: Main Uses and Benefits

The primary therapeutic role of this combination medication is commonly used to help with the daily, long-term management of chronic, obstructive breathing conditions. It is relevant for managing symptom clusters linked to inflammatory or irritative states. This medication is applied across core therapeutic areas involving chronic respiratory conditions.

The medicine is relevant for easing symptoms in two main conditions: Chronic Obstructive Pulmonary Disease (COPD), including chronic bronchitis and emphysema, and Persistent Asthma, particularly in adolescents (age 12) and adults whose condition is not adequately controlled by a single inhaled anti-inflammatory drug. It targets symptoms that interfere with daily functioning, such as recurring wheezing, chest tightness, and chronic shortness of breath.

The general clinical scenario involves a long-term daily maintenance approach to support the management of stable airflow and assist with managing the frequency of exacerbations or flare-ups. This helps the patient cope more steadily with difficult episodes.

“The therapeutic benefit supports relief from symptoms that interfere with daily functioning across the full day and night.”

---

Quick Fact: Relief for Respiratory Discomfort

Property	Description
Use Category	Daily Long-term Maintenance
Main Indication 1	COPD (Chronic Bronchitis/Emphysema)
Main Indication 2	Persistent Asthma (Age 12)
Primary Benefit	Supports the management of chronic symptoms and reduces exacerbation risk

Regulatory References

1. European Medicines Agency overview of Relvar Ellipta

Absolute Contraindications

The medicine is strictly contraindicated in patients with a known severe hypersensitivity to milk proteins or to the active ingredients (Fluticasone furoate, Vilanterol). It must not be used for treating acute episodes of asthma or COPD (e.g., status asthmaticus), as it is intended for long-term daily maintenance only. Concurrent use of any other medication containing a Long-Acting Beta2-Adrenergic Agonist (LABA) is prohibited.

---

Age-Related and Indication Eligibility

The medicine is approved for asthma maintenance in adults and adolescents (≥ 12 years). For the COPD indication, use is restricted to adults ≥ 18 years. Use is not recommended for children under 12 years of age for asthma, as safety and efficacy are not established in this group.

---

Conditional Use and Restrictions

Caution is required, and use may be restricted, for patients with severe cardiovascular disease or specific metabolic conditions like diabetes mellitus. Patients with moderate to severe hepatic impairment (liver problems) should typically use the lower dose strength. Use during pregnancy is only considered if the expected benefit outweighs the potential risk.

Interactions with Other Medicines and Products

The official interaction profile for Релвар Эллипта (fluticasone furoate/vilanterol) requires careful consideration of several concomitant product categories. Interactions are primarily defined by the metabolism of the active ingredients and their pharmacological effects.

Pharmacokinetic Interactions

Strong Cytochrome P450 3A4 (CYP3A4) Inhibitors

Concomitant use with strong CYP3A4 inhibitors, such as ketoconazole, is generally not recommended. Both fluticasone furoate and vilanterol are extensively metabolized by CYP3A4. Co-administration increases the systemic exposure of both components, potentially leading to increased systemic corticosteroid effects and cardiovascular effects from vilanterol. Caution and monitoring are especially required for patients with moderate or severe hepatic impairment.

Pharmacodynamic Interactions

Beta-Adrenergic Blocking Agents (Beta-blockers)

The use of non-selective beta-blockers is not recommended as they may antagonize the therapeutic, bronchodilating effect of vilanterol and may precipitate bronchospasm.

Other Long-Acting Beta-2 Adrenergic Agonists (LABAs)

Co-administration with other LABA-containing medicines is to be avoided due to the risk of additive sympathetic effects and potential overdose.

Cardiovascular-Potentiating Agents

Caution is advised when co-administering with drugs known to prolong the QTc interval, Monoamine Oxidase Inhibitors (MAOIs), or Tricyclic Antidepressants (TCAs). These agents may potentiate the cardiovascular effects (e.g., increased heart rate and blood pressure) associated with vilanterol.

Non-Potassium-Sparing Diuretics

Co-administration requires caution, as non-potassium-sparing diuretics may potentiate the risk of hypokalemia associated with beta-agonist use.

Релвар Эллипта is a fixed-dose combination product containing fluticasone furoate and vilanterol, both delivered directly to the pulmonary tissues via inhalation.

Fluticasone furoate is a synthetic glucocorticoid that acts as an agonist at the intracellular glucocorticoid receptor (GR). Upon binding to the GR, this complex translocates to the nucleus. Here, it modulates gene transcription by binding to glucocorticoid response elements (GREs) to activate anti-inflammatory gene expression, and by inhibiting pro-inflammatory transcription factors, such as NF-kappaB and AP-1. This results in the reduced synthesis and release of various inflammatory mediators (e.g., cytokines, chemokines, eicosanoids) from multiple cell types (e.g., eosinophils, mast cells, lymphocytes). Systemically, it leads to a reduction in the influx and activation of inflammatory cells within the airway mucosa.

Vilanterol is a long-acting selective beta2-adrenergic receptor left(beta2 -AR ight) agonist targeting the airway smooth muscle cell membrane. Vilanterol's binding activates the beta2 -AR, which couples to G s protein to stimulate adenylyl cyclase. This enzyme catalyzes the conversion of ATP to cyclic adenosine monophosphate (cAMP). The resulting increase in intracellular cAMP concentration activates protein kinase A (PKA), leading to a phosphorylation cascade that ultimately causes bronchial smooth muscle relaxation and resultant airway lumen dilation.

How to Use Relvar Ellipta (Fluticasone Furoate/Vilanterol)

Relvar Ellipta is an inhalation powder administered via the Ellipta inhaler device for maintenance treatment. This medicine is not to be used for the immediate relief of sudden breathing problems, which requires a separate rescue inhaler.

Official Dosing and Schedule

Patient Group	Recommended Dosage	Frequency
Adults (Asthma/COPD)	One inhalation of 100/25 mcg	Once Daily
Adolescents (Asthma)	One inhalation of 100/25 mcg	Once Daily
Maximum Dose (Asthma)	One inhalation of 200/25 mcg	Once Daily

The medicine should be taken at the same time every day to maintain a consistent therapeutic effect. Do not take more than one inhalation within a 24-hour period. If a dose is missed, take the next scheduled dose at the usual time the next day; do not double the dose.

Administration Procedure and Constraints

The Ellipta inhaler must not be shaken. The dose is prepared by sliding the cover down until a 'click' is heard, exposing the mouthpiece and advancing the dose counter.

The patient must inhale the medicine with one long, steady, deep breath through the mouthpiece, then hold the breath for several seconds before breathing out slowly. After inhalation, the patient is required to rinse their mouth with water and spit it out (do not swallow) to reduce the risk of oropharyngeal candidiasis. Dosage adjustment is generally not required for the elderly or those with renal impairment, but caution is advised, and the dose should not exceed 100/25 mcg in patients with moderate to severe hepatic impairment.

Research Evidence / Overview of Studies for Релвар Эллипта

---

Evidence for Use in Chronic Obstructive Pulmonary Disease (COPD)

Research into Релвар Эллипта was studied for conditions characterized by fluctuating or episodic manifestations like COPD. These studies involved large, controlled clinical trials (RCTs) and observational settings. Researchers examined outcomes describing episodic or acute changes, such as the rate of moderate or severe COPD flare-ups (exacerbations), and monitored changes in lung function markers, like FEV1, over specific time intervals. Research explored the combination compared to placebo or other investigational treatments used in the studies. Findings describe patterns observed in the studies regarding the frequency of exacerbations and research highlights changes measured during the study period in lung function. Research included monitoring for the incidence of specific adverse events as part of the safety evaluation.

---

Evidence for Use in Asthma

For persistent asthma, studies explored the combination in adolescents and adults who met the study criteria for inhaled corticosteroid use. The research design included controlled trials that compared the combination against placebo or another established inhaled combination of similar drug classes. The main focus was on measuring outcomes reflecting daily functioning or activity level, such as patient scores on asthma control tests, and objective measures of lung function. What the studies reported was a pattern observed in the studies where measures of asthma control and lung function were measured to be different when compared to the specific comparator treatments used in the trials.

---

What is Still Uncertain About Релвар Эллипта Research

Long-term effects are not fully established regarding the impact on overall disease progression, such as mortality, in COPD patients, as the most definitive studies have time limitations. Comparative evidence is lacking for certain fixed combinations, and subgroup findings are uncertain or evidence is limited for patients with certain specific co-existing medical conditions, who were often excluded from the original RCTs. The results apply only to the populations studied, and research does not determine whether an individual will respond similarly outside of the specific conditions under which the study was conducted.

Common questions about Релвар Эллипта (FAQ)

Q: Why is this medication only taken once a day?

Official product information states that this medication contains the component vilanterol, which is classified as a long-acting beta2-agonist. This component is designed to provide sustained opening of the airways. This extended duration of action is why the medicine is prescribed as a once-daily maintenance dose.

Q: What condition is Релвар Эллипта most commonly prescribed for?

According to regulatory documentation, the medication is officially indicated for the regular maintenance treatment of asthma in adults and adolescents (age 12 and older). It is also indicated for the symptomatic treatment of adults with Chronic Obstructive Pulmonary Disease (COPD) who have a history of acute worsening of symptoms (exacerbations).

Q: Can Релвар Эллипта be used by people who also have heart conditions?

Official product information notes that the medicine should be used with caution in patients with severe cardiovascular disease, heart rhythm abnormalities, or high blood pressure. This is because the long-acting beta2-agonist component has the potential for sympathetic effects on the heart.

Q: Are there specific symptoms that require immediate medical attention while using this medicine?

Regulatory documents highlight that if you experience an immediate, severe worsening of your breathing or wheezing right after inhalation, this is known as paradoxical bronchospasm. If this occurs, regulatory guidance states that the medicine should be stopped and immediate medical attention should be sought.

Q: Is the medication intended to replace other forms of maintenance therapy?

The medication is indicated for specific patient groups, including those who are not adequately controlled on an inhaled corticosteroid alone. It is also indicated for those transitioning from separate inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) therapies.

Q: How can I tell if the inhaler device is working correctly?

The Ellipta inhaler device incorporates a dose counter to confirm proper function. When you slide the cover open, the inhaler should produce a 'click,' and the dose counter must simultaneously count down by one number. This mechanism confirms that the medicine is correctly advanced and ready to be inhaled.

Q: Are there any contraindications related to glaucoma with this medication?

Official safety information notes that the inhaled corticosteroid component can potentially increase the risk of developing cataracts and glaucoma. Therefore, patients with pre-existing eye conditions like glaucoma require close monitoring.

Q: What is the meaning of the number that appears on the inhaler device?

The number displayed on the inhaler is a dose counter. This number indicates the precise amount of doses remaining in the device. Official instructions specify that the inhaler should be discarded when the counter reaches the number '0'.

Q: Is it normal to feel a change in my voice after using Релвар Эллипта?

Yes, regulatory adverse reaction tables list hoarseness (dysphonia) as a common adverse reaction that has been reported. This effect is generally associated with the use of inhaled medications, particularly those containing corticosteroids.

Q: How long does it typically take to notice the expected effects of Релвар Эллипта?

Clinical studies, as noted in the official product information, indicate that patients commonly experience an initial improvement in lung function within 15 to 17 minutes of taking the dose.

Q: Can Релвар Эллипта affect blood sugar levels?

Official safety documents report that there have been incidents of increased blood glucose levels, which is medically referred to as hyperglycaemia. Due to this potential effect, use requires careful consideration for patients with a history of diabetes mellitus.

Q: Are there any known issues with using Релвар Эллипта and common cold or flu medications?

The active ingredients are primarily metabolized by a specific liver enzyme called CYP3A4. Regulatory documents caution that strong inhibitors of this enzyme are not recommended. Patients should consult a healthcare provider before taking any new medication, including cold or flu remedies, to check for potential drug-drug class interactions.

Q: Can Релвар Эллипта cause sleeplessness or anxiety?

Official adverse reaction data includes reports of certain central nervous system effects. Sleep disorders (insomnia), anxiety, and tremor are listed as rare adverse reactions that have been reported during clinical use.

Q: Can this medication cause dry mouth or throat irritation?

Yes, official safety information lists dry mouth and a sore throat as potential side effects associated with this medication. These effects may sometimes occur due to the inhalation of the dry powder formulation.

Q: Is it safe to drink alcohol while using Релвар Эллипта?

Official regulatory labeling does not contain a specific interaction warning between this medication and alcohol. However, alcohol consumption may have overlapping effects on the heart or blood sugar levels. Patients should discuss their use of alcohol with their healthcare provider.

Q: What does official guidance say about discontinuing the use of Релвар Эллипта?

Official regulatory guidance explicitly states that therapy should not be stopped without direct supervision from a physician. Abruptly discontinuing the medication may cause symptoms to return or worsen.

Q: Does this drug have a Boxed Warning in the US?

The US labeling (Breo Ellipta) includes a Boxed Warning for the entire class of long-acting beta2-agonists (LABAs) when used for asthma. This warning describes a potential increased risk of asthma-related death. The medication is explicitly not approved for the acute relief of asthma symptoms.

Storage and Disposal Requirements

Relvar Ellipta must be stored in its original, sealed foil tray to protect the dry inhalation powder from moisture, according to official labeling. The storage temperature must not exceed 30 C.

Once the foil tray is opened, the medicine has a limited in-use shelf-life of 6 weeks. The product must be discarded after this 6-week period or after the expiration date, whichever comes first.

For safety, the inhaler must be stored out of the sight and reach of children.

Disposal instructions mandate that unused or expired inhalers must not be thrown into household trash or wastewater. The product must be disposed of according to local regulatory requirements, typically by returning it to a pharmacy.